这是自今年7月《四川省种子独角兽企业备案培育办法（试行）》发布以来，首次遴选出的高潜力科技 型初创企业，温江区此次入选拟备案名单的企业是来自生物医药领域的通瑞生物制药（成都）有限公 司、东方妍美（成都）生物技术股份有限公司。 近日，四川省科学技术厅发布的首批33家"种子独角兽"企业拟备案名单已通过公示，33家种子独角兽企 业通过评审备案，成都市温江区2家企业入选。 此外，东方妍美是一家聚焦Ⅲ类医美器械和特殊医学用途配方食品的研产销一体化医疗健康企业，专注 于微球制备工艺、高分子材料改性技术、凝胶交联技术、凝胶与微球混合技术的开发与研究。其正在温 江建设集研、产、销于一体的总部基地，打造5条现代化生产线、医美参观体验中心，构建从原料研发 到临床应用的完整产业链。 据介绍，通瑞生物是一家专注于放射性药物（核药）的CRDMO（合同研究、开发和生产）企业，为全 球客户提供从临床前到商业化生产的一体化服务。在温江建有28000平方米的研发和生产基地，已支持 14个前沿的Ac-225核素标记药物的开发。 近年来，温江区科学技术局聚焦"3+6"现代化产业体系建设，以强化科技型企业创新主体地位为牵引， 以提升企业自主创新能力 ...

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on imaging and radiotherapy [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear imaging equipment, and radiotherapy devices [2] Development Environment - The Chinese government has implemented various policies to support the nuclear medicine industry, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - These policies aim to enhance innovation, expand clinical applications, and create new opportunities for related enterprises [6] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant technological advancements, moving from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Dongfang, East Cheng Pharmaceutical, and Yuanda Medical, with East Cheng holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new drug development, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in nuclear medicine services [20]